expert perspectives

in Chronic Lymphocytic Leukemia

Expert Perspectives in Chronic Lymphocytic Leukemia to Cover Key Topics in Chronic Lymphocytic Leukemia Treatment


Expert Perspectives delivers health care providers with insights from key thought leaders on the latest advancements and current practices in medicine, in a concise and timely format. This issue of Expert Perspectives in Chronic Lymphocytic Leukemia will feature selected topics in Chronic Lymphocytic Leukemia that we hope you will find of value in your clinical practice.

The clinicians who were surveyed selected the following experts and topics.

Community-Selected Experts:

Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Boston, MA

Susan O’Brien, MD

Division of Hematology/Oncology
Department of Medicine
University of California, Irvine
Irvine, CA

William G. Wierda, MD, PhD

Professor and D.B. Lane Cancer Research Distinguished Professor
Section Chief – Chronic Lymphocytic Leukemia
Leukemia Center Medical Director
Department of Leukemia, Division of Cancer Medicine
Executive Medical Director, Inpatient Medical Services
The University of Texas MD Anderson Cancer Center
Houston, TX

Community-Selected Topics: 

Expert Roundtables

    Emerging Standards in the Frontline Treatment of Chronic Lymphocytic Leukemia
    Chronic Lymphocytic Leukemia: Perspectives on Early Intervention
    Survival in Older Patients With Chronic Lymphocytic Leukemia: Treatment and Nontreatment Factors
    Novel Agents and Combinations for Treatment-Naive Chronic Lymphocytic Leukemia

Clinical Topic Updates

    Head-to-Head Data: Novel Agents in Relapsed/Refractory Chronic Lymphocytic Leukemia
    Exploring the Next-Generation Bruton Tyrosine Kinase, BCL-2, and PI3Kδ Inhibitors
    Chronic Lymphocytic Leukemia: Understanding Treatment Resistance Mechanisms
    Richter Transformation in Chronic Lymphocytic Leukemia: Detection and Research Directions

Patient Care Perspectives

    Chronic Lymphocytic Leukemia: Geriatric Assessment and Support During Treatment
    Responses to Vaccines and Recommendations for Patients With Chronic Lymphocytic Leukemia
    Reducing Toxicity From Chronic Lymphocytic Leukemia Treatment
    Role of Hematopoietic Stem Cell Transplantation in High-Risk Chronic Lymphocytic Leukemia

More in CLL



Optimal Duration and Dose of Novel Agents for Chronic Lymphocytic Leukemia

Expert Roundtables by Jennifer R. Brown, MD, PhD, Jan A. Burger, MD, PhD, Anthony Mato, MD, MSCE

Novel agents such as ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, and idelalisib, a phosphatidylinositol 3-kinase (PI3K) inhibitor, achie...READ MORE



Interpreting Chronic Lymphocytic Leukemia Prognostic Markers in the Novel Treatment Era

Expert Roundtables by Jennifer R. Brown, MD, PhD, Jan A. Burger, MD, PhD, Anthony Mato, MD, MSCE

Prognostic markers for chronic lymphocytic leukemia (CLL) were developed in the previous treatment era and have the potential to take on new or per...READ MORE



Role of Age and Fitness in Selecting Treatment for Chronic Lymphocytic Leukemia

Expert Roundtables by Jennifer R. Brown, MD, PhD, Jan A. Burger, MD, PhD, Anthony Mato, MD, MSCE

The risks of administering chemoimmunotherapy (CIT) such as fludarabine, cyclophosphamide, and rituximab (FCR) in advanced age have been clearly de...READ MORE

More In Oncology


High-Risk Chronic Lymphocytic Leukemia: Insights and Approaches

Expert Roundtables by Jennifer R. Brown, MD, PhD; John C. Byrd, MD; and Susan O’Brien, MD

HR-Positive HER2-Negative Breast Cancer

Second-line Treatment for Advanced/Metastatic HR+ HER2- Breast Cancer

Clinical Topic Updates by Joseph A. Sparano, MD, FACP

HR-Positive HER2-Negative Breast Cancer

First-line Therapy for Advanced HR+ HER2- Breast Cancer

Patient Care Perspectives by Joseph A. Sparano, MD, FACP